Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation (2013 - 2016)

Viridian Therapeutics, Inc.\DE's Accumulated Depreciation history runs 4 years deep, the most recent figure standing at $881000.0 for Q3 2016.

• On a quarterly basis, Accumulated Depreciation rose 27.31% year-over-year to $881000.0 in Q3 2016; TTM through Sep 2016 was $881000.0, a 27.31% increase from a year earlier, with the FY2015 full-year figure at $739000.0, up 33.15% from the prior year.
• Accumulated Depreciation climbed to $881000.0 in Q3 2016 per VRDN's latest filing, from $834000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $881000.0 in Q3 2016 and bottomed at $411000.0 in Q4 2013.
• The 4-year median for Accumulated Depreciation is $645000.0 (2015), against an average of $649437.1.
• Across the five-year window, Accumulated Depreciation surged 35.04% in 2014 and climbed 27.31% in 2016, its largest moves.
• Year by year, Accumulated Depreciation stood at $411000.0 in 2013, then jumped by 35.04% to $555000.0 in 2014, then surged by 33.15% to $739000.0 in 2015, then climbed by 19.22% to $881000.0 in 2016.
• Per Business Quant, the three latest VRDN Accumulated Depreciation figures stand at $881000.0 (Q3 2016), $834000.0 (Q2 2016), and $786000.0 (Q1 2016).